Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda’s Hat Trick Marks The First New Molecular Entity Of 2013

This article was originally published in The Pink Sheet Daily

Executive Summary

Takeda’s type 2 diabetes drug alogliptin – on its third pass through FDA – was cleared Jan. 25 as a single agent as Nesina, in combination with metformin as Kazano and in combination with pioglitazone as Oseni.

Advertisement

Related Content

Takeda’s U.S. Approval For Alogliptin Boosts Prospects Of Contrave And TAK-875
An NME Surge After The Patent Cliff? Reinvention Of R&D Starts Paying Off In 2013 New Product Candidates
Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High
In A Changing Diabetes Drug Market, Who Will Come Out On Top?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS074817

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel